SERUM INTERLEUKIN-33 LEVELS ARE ELEVATED BUT NOT ASSOCIATED WITH DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS

ULUSOY H., AKGÖL G., GÜLKESEN A., KAYA A., KAMAN D.

ACTA MEDICA MEDITERRANEA, vol.36, no.6, pp.3293-3298, 2020 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 36 Issue: 6
  • Publication Date: 2020
  • Doi Number: 10.19193/0393-6384_2020_6_521
  • Journal Name: ACTA MEDICA MEDITERRANEA
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE
  • Page Numbers: pp.3293-3298
  • Keywords: Ankylosing spondylitis, Disease activity, Interleukin, IL-33, Rheumatoid arthritis, ANKYLOSING-SPONDYLITIS, IL-33, PATHOGENESIS, INVOLVEMENT, CYTOKINE, CRITERIA, HEALTH, BATH, SST2, ST2
  • Ondokuz Mayıs University Affiliated: Yes

Abstract

Introduction. Interleukin (IL)-33 is a new member of the IL-1 superfamily. After cellular damage, IL-33 is released into the extracellular space and functions as an alarmin to induce the innate immunity. Recent studies suggest that IL-33 can also induce T helper-1 (Th1), Th2 and Th17 mediated adaptive immune responses. So, as a pro-inflammatory cytokine, IL-33 plays an important role in the pathogenesis of autoimmune and inflammatory diseases. In this recpect, we also assessed the effect of serum IL-33 level in rheumatoid arthritis (RA) and ankylosing spondylitis (AS) which are the most common inflammatory arthritis.